Clik here to view.
Provectus Biopharmaceuticals’ Phase 1 PV-10 Data on Liver Cancer Presented at...
KNOXVILLE, Tenn. Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”),...
View ArticleClik here to view.
クインタイルズとクエスト・ダイアグノスティクスがQ2ソリューションズを創立
米ノースカロライナ州リサーチ・トライアングル・パーク & ニュージャージー州マディソン （ビジネスワイヤ） —...
View ArticleClik here to view.
昆泰与Quest Diagnostics推出Q2 Solutions
北卡罗莱纳州研究三角园区和纽约州麦迪逊 (美国商业资讯)–昆泰和Quest Diagnostics今天宣布推出其联合临床试验实验室服务公司Q2 Solutions。Q2 Solutions汇总了两家母公司的临床试验实验室业务，可为生物制药业客户提供生物制药业快速演进所需的多元化能力和端到端服务。今天推出的Q2 Solutions是之前宣布的全球性临床试验实验室服务合资企业交易完成的结果。...
View ArticleClik here to view.
AstraZeneca and Ironwood Report Positive Top-Line Data from Phase III IBS-C...
SHANGHAI & CAMBRIDGE, Mass. AstraZeneca Pharmaceuticals Co., Ltd. and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that top-line data demonstrate linaclotide met all primary and...
View ArticleClik here to view.
新規抗精神病薬「REXULTI®（レキサルティ）」 成人の統合失調症と大うつ病補助療法の2つの適応で米国FDAが承認
東京 （ビジネスワイヤ） — 大塚製薬株式会社（本社：東京都、代表取締役社長：樋口達夫、以下「大塚製薬」）とH.ルンドベックA/S（本社：デンマーク、コペンハーゲン、社長兼CEO：コア・シュルツ、以下「ルンドベック社」）は...
View ArticleClik here to view.
International Federation of Psoriasis Associations: Global psoriasis survey...
STOCKHOLM Today, at the 4th World Psoriasis & Psoriatic Arthritis Conference, the International Federation of Psoriasis Associations, IFPA, presents the results of a global survey to identify...
View ArticleClik here to view.
Dr. Reddy’s Announces the Launch of MEMANTINE HYDROCHLORIDE TABLETS, USP
HYDERABAD, India Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic version of NAMENDA®...
View ArticleClik here to view.
AMCo acquires Australian company Boucher and Muir
LONDON The British-based international niche pharmaceutical business AMCo has acquired the Australian pharmaceutical company, Boucher and Muir (‘BNM’). BNM was set up in 1957 and has grown to become...
View ArticleClik here to view.
Takeda Submits New Drug Application for Ixazomib for Patients with...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that a New Drug Application (NDA) has been submitted to the United States (U.S.) Food and Drug...
View ArticleClik here to view.
Multi-Site Study Validates End-to-End RNA-Seq Sample Prep Workflow for Human...
SAN CARLOS, Calif. & PISCATAWAY, N.J. A multi-site study has clinically validated an end-to-end workflow for the collection, storage, transport and preparation of human whole blood samples for...
View ArticleClik here to view.
CANbridge Acquires License for Apogenix’s APG101 Onco-Immunotherapy in...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive license agreement with...
View ArticleClik here to view.
ProNova凭借荷兰交易拓展欧洲业务
田纳西州马里维尔 (美国商业资讯)–阿姆斯特丹的一家新设质子疗法中心已选中ProNova Solutions作为设备供应商，该中心计划在2018年开始治疗患者。 阿姆斯特丹质子疗法中心(APTC)是学术医疗中心、阿姆斯特丹自由大学医疗中心和荷兰癌症研究所的合作项目，该中心宣布已选用ProNova为该新设施提供治疗系统，该设施每年能够为约600例患者提供质子疗法。 ProNova...
View ArticleClik here to view.
Provectus Biopharmaceuticals, Sinopharm-China State Institute of...
KNOXVILLE, Tenn. Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”),...
View ArticleClik here to view.
武田递交ixazomib用于复发/难治多发性骨髓瘤患者的新药申请
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE: 4502)今天宣布，已向美国(U.S.)食品药品管理局(FDA)递交ixazomib的新药申请(NDA)，ixazomib是口服蛋白酶体抑制剂类研究药物，用于治疗复发和/或难治多发性骨髓瘤。...
View ArticleClik here to view.
QImaging® Introduces New OEM Camera Platform and Web Portal for Biomedical...
SURREY, British Columbia QImaging, a manufacturer of scientific cameras for life science and OEM applications, launched a new QI OEM camera platform designed specifically to enhance instrument...
View ArticleClik here to view.
武田薬品が再発性／難治性の多発性骨髄腫患者の治療薬ixazomibで新薬承認申請
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ）– 武田薬品工業株式会社（TSE: 4502）は本日、ixazomibの新薬承認申請（NDA）を米食品医薬品局（FDA）に行ったと発表しました。ixazomibは経口治験薬としてのプロテアソーム阻害薬で再発性もしくは難治性または両方の多発性骨髄腫患者の治療を目的としています。...
View ArticleClik here to view.
THERAVECTYS to Present Detailed Phase I/II Results from the First-Ever...
PARIS THERAVECTYS, a Paris-based, fully-integrated discovery & clinical development company specialized in lentiviral vector-based therapeutic vaccines and T-cell therapies announced that...
View ArticleClik here to view.
テラヴェクティス、レンチウイルスベクターを使用した治療用ワクチンの初の第I/II相試験から得た詳細結果を2015年HIV治療シンポジウムで発表へ
パリ （ビジネスワイヤ） — パリを拠点とする完全統合型の創薬・臨床開発企業としてレンチウイルスベクターを使用した治療用ワクチンとT細胞療法を専門とするテラヴェクティスは本日、当社の第I/II相試験から得た詳細結果を、 「第8回国際エイズ学会HIV基礎研究・治療・予防会議」（IAS...
View ArticleClik here to view.
GenoLogics Releases Clarity LIMS X as Part of Illumina SeqLab
REDWOOD CITY, Calif. GenoLogics today announced the availability of Clarity LIMS X, an edition of its industry-leading laboratory informatics platform. Optimized for use with Illumina® SeqLab, the X...
View ArticleClik here to view.
Saki America Relocates Office to Fremont, California
SAN JOSE, Calif. Saki Corporation, an innovator in the field of automated optical inspection equipment, announces the relocation of the Saki America office to Fremont, California. The new office,...
View Article